Target and Technology
Brentuximab vedotin (ADCETRIS) is an antibody-drug conjugate (ADC) that targets CD30 which is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma, but not commonly found on healthy cells. Brentuximab vedotin uses our proprietary ADC technology and is composed of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE when internalized into CD30-expressing cells, resulting in target cell death.
We are developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the collaboration, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has commercialization rights in the rest of the world. The companies are funding joint worldwide development costs on a 50:50 basis, except in Japan where Takeda is fully responsible for development costs.
We are conducting a comprehensive clinical development program in more than 70 corporate and investigator clinical trials, including three phase 3 studies designed to evaluate the potential of brentuximab vedotin in earlier lines of its approved indications as well as in many additional types of CD30-expressing lymphomas. Safety and efficacy of brentuximab vedotin in these investigational programs have not been established.
Phase 3 clinical trials:
- ECHELON-1 trial in frontline classical Hodgkin lymphoma (sBLA accepted for filing and granted Priority Review with PDUFA date of May 1, 2018)
- ECHELON-2 trial in frontline mature T-cell lymphomas (also known as PTCL) (enrollment complete)
- CHECKMATE 812 trial in combination with nivolumab for relapsed/refractory Hodgkin lymphoma